Targeting STING Pathway Triggers Cytotoxic and Immune Responses Against Meningioma - News Center
Activation of the STING pathway using the STING agonist 8803 can target both meningioma tumor cells and intratumoral immune cells to produce potent antitumor responses.
Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot
Pfizer is invoking federal preemption to avoid liability over Depo-Provera's alleged links to meningiomas despite thousands of lawsuits alleging inadequate warnings.
